Maxim Group analyst Jason Kolbert came out today with a few insights on AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), after the company announced that the independent Data and Safety Monitoring Board (DSMB) gave the approval to continue the pivotal ZoptEC study in women with advanced, recurrent or metastatic endometrial cancer. Kolbert rates Aeterna Zentaris shares a Buy, with a $2 price target.
Kolbert noted, “The DSMB’s decision follows completion of its pre-specified second interim analysis on efficacy and safety for the ZoptEC Phase 3 trial at approximately 192 events. In April 2015, the DSMB made the same recommendation following its first pre-specified analysis on safety and futility at approximately 124 events. A final analysis of the data is expected at approximately 384 events.”
“We see compelling value ahead in this company across multiple programs. Success with the pivotal program is not being factored into the current valuation by Wall Street, in our opinion, nor is the return of Macrilen. In fact we see Macrilen as representing a paradigm shift in the adult growth hormone deficiency (AGHD) marketplace. The current test, insulin tolerance is long and burdensome compared to Macrilen. As such Macrilen could expand the market.” the analyst continued.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of -15.1% and a 27% success rate. Kolbert has a -72.4% average return when recommending AEZS, and is ranked #3773 out of 3775 analysts.
Out of the 3 analysts polled by TipRanks, 2 rate Aeterna Zentaris stock a Buy, while 1 rates the stock a Hold. With a return potential of 1431.5%, the stock’s consensus target price stands at $1.13.